Abstract
Introduction Altered metabolism may occur early in Alzheimer’s disease (AD). We used untargeted high-resolution metabolomics in the cerebrospinal fluid (CSF) in mild cognitive impairment (MCI) to identify these alterations.
Methods CSF from 92 normal controls and 93 MCI underwent untargeted metabolomics using high-resolution mass spectrometry with liquid chromatography. Partial least squares discriminant analysis was used followed by metabolite annotation and pathway enrichment analysis (PES). Significant features were correlated with disease phenotypes using spearman correlation.
Results We identified 294 features differentially expressed between the 2 groups and 94 were annotated. PES showed that pathways related to sugar regulation (N-Glycan, p=0.0007; sialic acid, p=0.0014; Aminosugars, p=0.0042; galactose, p=0.0054) homocysteine regulation (p=0.0081) were differentially activated and significant features within these pathways correlated with disease phenotypes.
Conclusion We identified a metabolic signature characterized by impairments in sugar and homocysteine regulation in prodromal AD. Targeting these changes may offer new therapeutic approaches to AD
Research in Context
Systematic review: The authors searched PUBMED and Google Scholar for previous reports of metabolomics and Alzheimer’s disease. Search Terms included: mild cognitive impairment, Alzheimer’s disease “AND” metabolism, metabolomics. This search identified multiple small studies that have conducted untargeted metabolomics in AD. This search resulted in the following findings: Prior studies have either included small samples, used targeted approaches, or focused on plasma profiling. In this study, we conducted a case-control untargeted high resolution metabolomic study on the CSF of a larger sample of normal cognition and mild cognitive impairment.
Interpretation: We discovered that pathways in sugar metabolism, homocysteine and tyrosine were dysregulated in AD. Further, features that were significantly different between MCI and normal cognition had different patterns of association with cognitive, neuroimaging and Amyloid and tau biomarkers.
Future direction: These pathways offer new potential targets for AD
Highlights
Metabolic signature is detectable in prodromal AD
Multiple sugar metabolism pathways are dysregulated in prodromal AD.
S-adenosylmethionine is under- and S-adenosylhomocysteine is overexpressed in AD
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institutes of Health [Grants number RF1AG051633, RF1AG057470, R01AG049752, R01AG042127
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
chang.liu2{at}emory.edu, Email: dpjones{at}emory.edu, kuppal2{at}emory.edu
